Sanofi, the French pharmaceutical behemoth, had a tumultuous year in 2025; ranging from milestone achievements to setbacks in some areas. Sanofi garnered attention for its efforts in the development of autoimmune technology through a
$500M deal with Evoq, they also pulled back on UK R&D investments paralleling other pharma's strategy.
Legal issues persist with lawsuits from Texas, accusing Sanofi of deceptive marketing and not disclosing risks associated with the blood thinner drug, Plavix, which were accompanied by a fine of $177M for anti-competitive behavior. Counterbalancing setbacks, Sanofi secured success in immunotherapy when its diabetes drug got the green light for EU approval and obtained significant backing from a $112M strategic investment from Sanofi Ventures for Lifordi Immunotherapeutics. Notably, it has committed at least
$20bn to US manufacturing through 2030. Sanofi’s CEO, notes the contribution of
AI in R&D, which supports their ongoing digital transformation. However, the company experienced declining share prices triggered by concerns over drug safety and trials falling short of expectations. Looking forward, Sanofi continues to engage in strategic partnerships and expediting trials through AI integration. Its long-term plans remain conducive to building a healthier world despite recent pitfalls.
Sanofi News Analytics from Thu, 20 Mar 2025 09:36:24 GMT to Fri, 21 Nov 2025 17:36:11 GMT -
Rating -1
- Innovation 3
- Information 4
- Rumor 5
